

May 11, 2023

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: 524372

Subject: Investors Presentation Q4 FY23 – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

This is in continuation to our earlier announcement dated May 08, 2023.

In accordance to the requirement of Regulation 30 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, please find enclosed copy of the Investor Presentation on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2023.

Copy of the Investor Presentation is also made available on the website of the Company at www.orchidpharma.com

You are requested to take the above on your record.

Thanking You,
For **Orchid Pharma Limited**

MARINA
PETER

Digitally signed by
MARINA PETER
Date: 2023.05.11
13:26:05 +05'30'

Marina Peter
Company Secretary & Compliance Officer
Encl. as above



Annual Results FY23


This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Orchid Pharma Ltd** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness


TOTAL INCOME




EBITDA




PAT




EXPENSES BREAKUP



LEVERAGE



LONG TERM DEBT FROM BANK



SUMMARY RESULTS

	Rs. In cr	
Particulars	Year 22-23	Year 21-22
Net Sales / Income from operations	666	557
Other Income	19	9
Total income	685	566
	-	-
Raw material cost	385	314
Employee benefit expenses	65	60
Finance costs	32	32
Depreciation and amortization expense	55	87
Other expenses	132	125
Total expenses	669	619
	-	-
Profit /(Loss) before exceptional items	16	-53

Thank You!